Literature DB >> 358918

Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

S Inoue, T Ohue, J Yamagishi, S Nakamura, M Shimizu.   

Abstract

Spontaneous mutants with various patterns of resistance to pipemidic acid (PPA), piromidic acid (PA), and nalidixic acid (NAL) were isolated from Escherichia coli K-12. Most mutants were less resistant to PPA than to PA and NAL, and some mutants resistant to PA and NAL were hypersusceptible to PPA. As for the mutants tested, resistance to the drugs was conferred by mutations at nalA and new nal genes designated as nalC and nalD, both of which were located at about 82 min on the recalibrated map. Resistance to PA and NAL was due to decreased sensitivity of the bacterial DNA synthesizing system to them and insufficient drug transport, whereas resistance to PPA was only due to the former.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 358918      PMCID: PMC352440          DOI: 10.1128/AAC.14.2.240

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS.

Authors:  G Y LESHER; E J FROELICH; M D GRUETT; J H BAILEY; R P BRUNDAGE
Journal:  J Med Pharm Chem       Date:  1962-09

2.  A NONSPECIFIC INCREASE IN PERMEABILITY IN ESCHERICHIA COLI PRODUCED BY EDTA.

Authors:  L LEIVE
Journal:  Proc Natl Acad Sci U S A       Date:  1965-04       Impact factor: 11.205

3.  Transduction of linked genetic characters of the host by bacteriophage P1.

Authors:  E S LENNOX
Journal:  Virology       Date:  1955-07       Impact factor: 3.616

4.  Mutants of Escherichia coli requiring methionine or vitamin B12.

Authors:  B D DAVIS; E S MINGIOLI
Journal:  J Bacteriol       Date:  1950-07       Impact factor: 3.490

5.  Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.

Authors:  A Sugino; C L Peebles; K N Kreuzer; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

Review 6.  Recalibrated linkage map of Escherichia coli K-12.

Authors:  B J Bachmann; K B Low; A L Taylor
Journal:  Bacteriol Rev       Date:  1976-03

7.  Piromidic acid, a new antibacterial agent: antibacterial properties.

Authors:  M Shimizu; S Nakamura; Y Takase
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

8.  Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase.

Authors:  M Gellert; M H O'Dea; T Itoh; J Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1976-12       Impact factor: 11.205

9.  High-efficiency liquid-scintillation counting of 14C-labelled material in aqueous solution and determination of specific activity of labelled proteins.

Authors:  T C Hall; E C Cocking
Journal:  Biochem J       Date:  1965-09       Impact factor: 3.857

10.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

View more
  32 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid.

Authors:  N Moniot-Ville; J Guibert; N Moreau; J F Acar; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 3.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1993       Impact factor: 9.546

4.  [Mechanism of action of quinolones].

Authors:  J T Smith
Journal:  Infection       Date:  1986       Impact factor: 3.553

5.  Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.

Authors:  I Morrissey; J George
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 6.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

7.  Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.

Authors:  K Hirai; H Aoyama; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 8.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

9.  Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth.

Authors:  D C Hooper; J S Wolfson; G L McHugh; M B Winters; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

10.  Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes.

Authors:  M Rella; D Haas
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.